Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Opioid Use Disorder
  • Age: Between 18 - 65 Years
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1. Adult volunteer able to provide written informed consent in English
    2. Current CJS incarceration (residing in a controlled environment) with pending release date (within 6 months of randomization) OR community CJS-involvement defined as:
      • Current CJS incarceration (residing in a controlled environment) with pending release date (within 6 months of anticipated randomization)
      • ommunity-dwelling volunteers with current CJS-involvement. Current CJS-involvement is defined as either 1) release from any CJS incarceration or detention, or 2) under community supervision
    3. Current or history of moderate-to-severe opioid use disorder
    4. Not planning to move out of state or to new location within 6-months post-release
    5. Willing to accept either XR-B or XR-NTX assignment

You may not be eligible for this study if the following are true:

    1. Medical or psychiatric disorders
    2. Pregnant, planning conception or breast-feeding
    3. Allergy, hypersensitivity or medical contraindication to either medication
    4. Chronic pain requiring opioid pain management
    5. On daily stable methadone or buprenorphine (SL-B) maintenance every day for past 30 days prior to incarceration or monthly XR-NTX or XR-BUP 30 days or longer prior to incarceration AND intending to remain on same form of methadone or buprenorphine or XR-NTX maintenance upon return to the community



If you are registered as a volunteer, please login to the dashboard to send referrals.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.